[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"focal-epilepsy-with-and-without-secondary-generalization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:focal-epilepsy-with-and-without-secondary-generalization":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100629181","prospective-study-of-postictal-psychotic-symptoms-occuring-after-video-eeg-monitoring-in-focal-epilepsies-100629181",false,"NCT07471334","Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies","Incidence of Postictal Psychotic Symptoms After a Video-EEG Monitoring : Impact of Focal Epileptic Seizures","INSPEV","Inclusion Criteria:\n\n* confirmed diagnosis of drug-resistant focal epilepsy\n* hospitalization for at least 5 days video-EEG (or SEEG) monitoring\n* capable of providing informed consent, able to communicate in French, and covered by a national health insurance plan\n\nExclusion Criteria:\n\n* Patients presenting with psychotic symptoms at baseline (V1), or who have had recent modifications (less than 15 days before admission) to their antiepileptic or psychotropic medications, will be excluded to reduce confounding factors in the assessment of postictal psychotic symptoms.","ALL","18 Years",{"count":20,"type":21},110,"ESTIMATED","INTERVENTIONAL",[24],"NA","Psychotic disorders are up to eight times more prevalent in patients with epilepsy compared to the general population. Among them, postictal psychosis (PIP) is a severe complication of focal epilepsy, characterized by a brief psychotic episode emerging days after a seizure. This project investigates a potentially attenuated and under-recognized manifestation-postictal psychotic symptoms (PPs)-that may arise following hospitalization in a video-EEG monitoring unit and might serve as an early indicator for future PIP.\n\nThe investigators hypothesize that the incidence of PPs is substantially higher than the 3% PIP prevalence reported in the literature and that their occurrence correlates with the intensity of epileptic activity triggered during video-EEG monitoring. The study has three main objectives: (1) to determine the incidence of PPs in patients with drug-resistant focal epilepsy, (2) to identify predictive factors associated with PPs, and (3) to assess the validity of the PQ-16 screening tool in this clinical context.\n\nA prospective monocentric study will be conducted in the video-EEG unit of Nancy University Hospital. One hundred and ten patients hospitalized for at least five days will be included. Psychiatric assessments will include standardized clinical interviews, Brief Psychiatric Rating Scale (BPRS) scoring, and self-report questionnaires. These evaluations will take place at three timepoints: baseline (V1), 3-5 days post-discharge (V2), and two months post-discharge (V3).\n\nThis study aims to facilitate the early identification of PPs and support the development of preventive strategies, ultimately improving psychiatric care and overall management in patients with epilepsy.",[27,28],"Focal Epilepsy With and Without Secondary Generalization","Psychotic Symptoms",[30,31,32],"postictal psychosis","epileptic psychoses","psychoses of epilepsy","NOT_YET_RECRUITING","2026-05-13",{"date":36,"type":37},"2026-05-15","ACTUAL",{"date":39,"type":21},"2026-07-01",{"date":41,"type":21},"2028-09-01",{"name":43,"class":44},"Central Hospital, Nancy, France","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100576983","psychological-and-psychiatric-assessment-in-patients-eligible-for-epilepsy-surgery-100576983","NCT06792383","Psychological and Psychiatric Assessment in Patients Eligible for Epilepsy Surgery","PsychoSurgery","Inclusion Criteria:\n\n* Patients aged 18 or older at the time of enrollment;\n* Patients with drug-resistant focal epilepsy followed at the Institute for at least 6 months;\n* Patients with drug-resistant focal epilepsy eligible for epilepsy surgery;\n* Patients capable of providing informed consent to participate in the study and for the processing of personal data.\n\nExclusion Criteria:\n\n* Patients with evident and\u002For diagnosed cognitive or psychiatric disorders that prevent participation in an interview, proper understanding of informed consent, or completion of questionnaires.",{"count":53,"type":21},180,[24],"The aim of the study is to describe the socio-demographic, clinical, psychological, and psychiatric characteristics of patients with drug-resistant focal epilepsy eligible for epilepsy surgery and any changes in these parameters over time after surgery. Additionally, the study seeks to describe the levels of quality of life, dissociative experiences, prevalence of various psychiatric symptoms, irritability, depressive symptoms, anxiety symptoms, and stigma perception in patients with drug-resistant focal epilepsy eligible for epilepsy surgery and any changes over time after surgery.",[27],[58,59,60,61],"epilepsy","quality of life","psychiatric symptoms","stigma","RECRUITING","2026-02-10",{"date":65,"type":37},"2026-02-12",{"date":67,"type":37},"2020-12-02",{"date":69,"type":21},"2026-12",{"name":71,"class":44},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":72},"100571173","real-world-clinical-response-to-cenobamate-early-add-on-in-france-germany-and-spain-100571173","NCT06716801","Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain","Observational Cohort Study on Adult Patients With Not-adequately Controlled FOcal-onset Seizures Treated With Cenobamate as Early adjUnctive Therapy in a Real-world Setting - FOCUS","Inclusion Criteria:\n\n1. Male and female patients ≥18 years old at the time of cenobamate treatment initiation.\n2. Patients with a diagnosis of epilepsy with focal-onset seizures, with or without secondary generalization.\n3. Patients under titration phase (i.e., maintenance dose not reached yet according to clinical judgement) with cenobamate as adjunctive therapy in third or fourth line with 1 to maximum 2 (for third line)\u002F3 (for fourth line) concomitant anti-seizure medications (ASMs).\n4. Patients who have not been adequately controlled despite treatment with 2 or 3 (maximum) ASMs before cenobamate treatment initiation (including concomitant ASMs started before initiating cenobamate).\n5. Patients with available retrospective data in medical charts, seizure diaries or patient's notes, including reliable information about seizure frequency (intended as the number of seizures and the corresponding time period) in the last 3 months before cenobamate treatment initiation.\n6. Written informed consent (including consent for the processing of personal data) signed by the patient, or by the legally designated representative in case of patient lacking capacity, prior to entering the study following local regulation.\n\nExclusion Criteria:\n\n1. Patients who meet any of the contraindications to the administration of cenobamate according to its approved Summary of Product Characteristics (SmPC).\n2. Patients with progressive neurodegenerative central nervous system (CNS) diseases or (benign or malignant) brain tumors.\n3. Patients with unstable psychiatric diagnosis, including suicidal ideation and behavior within 6 months prior to enrolment, current psychotic disorder, or acute mania.\n4. Patients with known substance abuse or dependence (except for caffeine and nicotine).\n5. Patients participating in any interventional study from cenobamate treatment initiation until enrolment visit.\n6. Patients with ongoing pregnancy or breast-feeding from cenobamate treatment initiation until enrolment visit.\n7. Patients who are seizure-free in the last 3 months before cenobamate treatment initiation.",{"count":81,"type":21},300,"OBSERVATIONAL","Aim of the study is to better characterize the clinical profile of adjunctive cenobamate by collecting data from the current standard clinical practice in France, Germany, and Spain, to describe the real-world clinical response among adult patients affected by focal epilepsy not adequately controlled despite a history of 2 or 3 ASMs before starting treatment with cenobamate (including previous and concomitant ASMs).",[27],[86,58],"focal-onset seizures","2025-09-16",{"date":89,"type":37},"2025-09-19",{"date":91,"type":37},"2024-12-19",{"date":93,"type":21},"2027-03",{"name":95,"class":96},"Aziende Chimiche Riunite Angelini Francesco S.p.A","INDUSTRY"]